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1. Introduction 
Vasopressin and glucagon have a number of similar 
actions in rat liver. Both stimulate glycogenolysis and 
phosphorylase a activity (reviewed in [ 11) and inhibit 
de novo lipogenesis [2-4]. In other respects, their 
actions are divergent. Thus vasopressin i hibits keto- 
genesis from oleate and stimulates oleate esterifica- 
tion, whereas glucagon opposes these effects [5]. The 
actions of glucagon are probably mediated via the 
CAMP system. Current opinion suggests hat the 
hepatic effects of vasopressin are not mediated by 
changes in [CAMP] [ 1,6]. A requirement for Ca2* in 
the action of the hormone has been indicated [1,7]. 
Stimulation of oleate esterification i  hepatocytes 
could result from increases in the concentration of 
the substrates of esterlfication (fatty acyl-CoA, glyc- 
erol-3-phosphate, dihydroxyacetone phosphate). 
Vasopressin the presence of oleate stimulated gly- 
colytic flux and oleate removal in hepatocytes [5]. 
Another explanation is that the stimulation of oleate 
esteritication iscaused by an increase in the specific 
activity of the enzymes of esterification (GPAT and 
DHAPAT). The activity of GPAT (and possibly 
DHAPAT) is decreased in fat cells by starvation or 
adrenaline and is increased by insulin (reviewed in [S]). 
In the whole liver, GPAT activity is decreased by 
streptozotocin-diabetes, anti-insulin serum and 
Abbreviations: CAMP, adenosine 3’,5’cyclic monophosphate; 
Bu,cAMP, dibutyryl CAMP; GPAT, glycerol-3-phosphate acyl- 
tmnsferase; DHAPAT, dihydroxyacetone phosphate acyltrans- 
ferase; Gd-Pase, glucosedphosphatase; BSA, bovine serum 
albumin 
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Bu2cAMP [9-l 11. Furthermore, fat cell microsomal 
GPAT may be inhibited by phosphorylation by CAMP- 
dependent protein kinase [ 121. Here, we describe the 
effects of vasopressin, glucagon and Bu,cAMP upon 
the activities of enzymes of fatty acid esterification i  
isolated hepatocytes. We conclude that the alterations 
in enzyme activity which we observe can in part 
explain the rates of esterification seen in the presence 
of these agents. 
2. Experimental 
2 .l . Materials 
[Arginine] vasopressin (grade VIII) and glucagon 
were from Sigma, Poole, Dorset. All enzymes, coenzy- 
mes and substrates were from the same source or BCL, 
Lewes, East Sussex. Radiochemicals (including CAMP 
assay kits) were from the Radiochemical Centre, 
Amersham. Isolated hepatocytes were prepared from 
fed, anaesthetized (Nembutal, 60 mg/kg body wt) 
female rats as in [ 13 ,141. Hepatocyte preparation 
commenced between 09:30 h and lo:30 h. 
2.2. Hepatocyte incubation and subcellular fraction- 
ation 
Hepatocyte incubation was done as in [ 15 ] in the 
presence of 1 mM oleate for 30 min in 40 ml total vol. 
Hormonal additions are described in the tables. Effec- 
tiveness of hormonal treatments was demonstrated by 
measurements of glucose and ketone body release. 
After incubation, hepatocyte suspensions were centri- 
fuged (mark 3, MSE Minor bench centrifuge, 30 s, 
ElsevierlNorth-Holland Biomedical Press 
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room temp.) and the pellets homogenized (20 upand- 
down strokes, hand-held Teflon-glass Potter-EIvehj~m 
homogenizer, adial clearance 0.1 mm) in 10 ml 
10 n&I Tris-HClll92 mM m~itol~59 mM sucrose/ 
1 mM EDTA/lO mM NaF (PH 7.4) (buffer A) at 
O&C. The homogenate was centrifuged at 620 X gav 
at 4°C for 10 min. The supernatant was decanted and 
cent~fuged at 7250 X gav for 10 min to produce a 
pellet (Fl) and a supematant (Sl). The Pl pellet was 
washed once by resuspension i  10 ml buffer A and 
centrifugation at 9000 X gav for 10 min. The pellet 
was resuspended in 1 ml buffer A and frozen in liquid 
Nz. The Sl fraction was centrifuged at 105 000 X gav 
for 60 min, the pellet (pz) was resuspended in 1 ml 
buffer A containing 1 mM dithiothreitol and was 
frozen in liquid Nz. 
Results of marker enzyme distributions in the 
hepatocyte subcellular f actions are shown in table 1. 
The P2 (microsomal) fraction was not markedly con- 
taminated with citrate synthase (mitochondri~ 
marker). The Pl (mitochondrial) fraction was exten- 
sively con~m~ated with arylesterase and G-6.Pase 
(microsomal markers) and may also contain peroxi- 
somes and lysosomes [23]. The specific activities of 
the microsomal markers were about equal in both Pl 
and P2 fractions. Both Pl and P2 fractions were 
enriched in microsomes and the Pl fraction was 
enriched in mitochond~a compared to the homog- 
enate. The subcellular f actionation procedure is based 
on that used in [ 111. It is not suggested that the pro- 
cedure used here produces highly purifted prep~ations 
of subcellular organelles. However, it was considered 
important o establish whether the relatively small 
changes in enzyme activities observed in homogenates 
were stable to subcellular f actionation and whether 
the changes were more apparent upon partial purifica- 
tion by fractionation. 
2 3. Enzyme and metabolife assays 
Enzymes were assyed at 30°C (except Gd-Pase 
which was assayed at 37*C) as follows by standard 
tec~ques: GPAT (EC 23.1 .15) at 0.5 mM [U-r’%]- 
glycerol3-phosphate (0.5 @ifpmol) at either 1.75 or 
6mlJmlBSA [9],DHAPAT(EC2.3.1.42) [ll], 
citrate synthase (EC 4.13.7) [ 16 f, arylesterase (EC 
3 .l .1.2) f 171. G&Pase was assayed in 0.2 ml contain- 
ing SO mM ~id~ole~l0 mM glucose&phosphate 
@H 7 .O) by measurement OfPi production [ 18 1. For 
assay, extracts were standardized to 5 mg protein/ml 
by the biuret method [ 191. Protein concentrations 
were sub~quen~y assayed by the Lowry method 1203. 
Glycerol-3-phosphate was measured as in [21] and 
CAMP in ~OH-neutr~ed HClO~-treated hepatocyte 
extracts was measured by the Gilman [22] procedure 
using a kit from the Radiochemical Centre. 
3. Results 
3 .l . Activities izf GPA T and DHAPA T in heparmytes 
treated wits v~~p~ssi~, g~~~~o~ and BuzcAMP 
Results are shown in table 2. For GPAT, assays 
were carried out at two BSA concentrations since 
BSA at 1.75 mglml has been reported to be optimal 
Table 1 
Activities of marker enzymes in hepatocyte subcellular fractions 
Enzyme Fraction Enzyme activity (munit/mp protein) 
Control +lO nM Control +lO PM 
vasopressin Bu,cAMP 
Citrate synthase Homogenate 81 i 3 (8) 80 i 5 (8) 89 i 3 (6) 86 * 4 (6) 
Pl 114* 8(11) 129i 5(11) llO* S(6) 121* 7(6) 
P2 13* l(11) 15t l(11) 18* 3 (6) 21 * 2 (6) 
Gd-Pase Homogenate 87 f 7 (7) 96 f 13 (7) 92* 9(5) 91* 7(5) 
Pl 196 i 13 (7) 203 f 16 (7) 184* 14(6) 2082 22(6) 
P2 195 ?r 19 (7) 238 f 2.5 f?)a 201 f 24 (6) 172 i 22 (6)a 
Arylesterase Homogenate 815 f 43 (8) 828 i 76 (8) 871 i 58f6) 842* 71(6) 
Pl 1567 f 85 (10) 1650 i 73 (10) 1577 i 106 (6) 1727 * 59 (6) 
P2 1685 f 125 (10) 2168 f 128 (lO)b 19611: 231(6) 1624 f 161 (6)a 
‘Enzyme acti&ies were assayed asin section 2.3. 1 munit is 1 nmol substrate utilizedlmin; results are means ttSEM with no. ohs..in 
parentheses; statistical significance, a P < 0.01~~ P < 0.001; paired t-test 
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for the microsomal isoenzyme whereas 6 mg/ml BSA 
is optimal for the mitochondrial isoenzyme [ 111. The 
standard incubation time was 3 min and the assay was 
linear with protein concentration and time. Vasopressin 
significantly increased GPAT activities in homogenates 
compared to control values when assayed at 6 mg 
BSA/ml. When assayed at 1.75 mg BSA/ml, GPAT 
activities in the homogenate were not significantly 
increased by vasopressin. This BSA level is optimal 
for the microsomal isoenzyme [1 l] whose activity is 
increased by vasopressin (table 2). Presumably there 
may be factors in the homogenates which interfere 
with the GPAT assay. Changes in GPAT activities are 
generally larger on a % basis in subcellular f actions 
than observed in homogenates. Vasopressin also 
increased GPAT activities in the Pl and P2 fractions 
at both BSA concentrations. Increases in GPAT activ- 
ity (assayed at 65 @I palmitoylCoA) were between 
16-3 l%, the largest increase being observed in the P2 
(microsomal) fraction at 1.75 mg BSA/ml. Although 
direct comparisons are invalid, a similar concentration 
of vasopressin i creases esterification of oleate by 
62% in rat hepatocytes [5]. DHAPAT activity is pres- 
ent in the fractions at only -1 O-20% of GPAT values. 
In this case, differences are less clear. In the Pl and 
P2 fractions, there are small but significant DHAPAT 
increases observed in the presence of vasopressin com- 
pared to control values. Because DHAPAT may be 
mainly peroxisomal, it may therefore sediment in 
Pl [23]. 
Glucagon and Bu+AMP decreased GPAT activities 
in hepatocyte homogenates. Bu&MP decreased 
GPAT activities in the P2 fraction (table 2). There 
were no significant effects of Bu,cAMP or glucagon 
on DHAPAT activities (table 2). BuzcAMP decreased 
GPAT in the perfused rat liver and in microsomal frac- 
tions derived from that preparation [lo]. Glucagon 
and Bu+AMP decreased oleate esterif’ication i  hepato- 
cytes [24]. Glucagon also significantly (P < 0.05) 
decreased vasopressin-stimulated ol ate esterification 
[ 51. (No comment was made about this finding at the 
time.) We have also shown that 10 (uM Bu+AMP 
decreased [ 1 -14C] oleate esterification i  hepatocytes 
from 0.16 + 0.02 to 0.10 + 0.01 pmol . min-* . mgwet 
wt hepatocytes-’ (n = 7, P < 0.05, Student’s f-test). 
In the course of the study of marker enzyme distri- 
bution, we observed that vasopressin significantly 
increased the specific activity of G-6-Pase in the P2 
fraction by 22% and of arylesterase by29%. Bu+AMP 
significantly decreased the specific activity of GdPase 
in the P2 fraction by 14% and of arylesterase by 17%. 
These treatments did not significantly change the spe- 
cific activities of the 3 marker enzymes in any other 
fraction. It should be emphasized that treatment with 
vasopressin or Bu&MP did not alter marker enzyme 
activities in homogenates (contrast his with GPAT). 
We do not see any obvious reasons for these vasopressin 
or Bu+AMP induced changes in marker enzyme activ- 
ities unless they selectively alter microsomal protein 
content. 
When GPAT or DHAPAT activity in P2 is expressed 
relative to arylesterase orGd-Pase activity, the signif- 
icant differences between hormonal treatments dis- 
appear. The % changes in GPAT and DHAPAT &tivi- 
ties are similar to those observed in marker enzyme 
activities in the P2 fractions. Other workers in this 
field have apparently encountered similar problems 
when attempting to relate GPAT activities to the 
activities of marker enzymes [9]. 
It is not possible to decide whether both mitochon- 
drial and microsomal GPAT activities [25] are affected 
by vasopressin and BQcAMP. Since P2 was relatively 
uncontaminated bymitochondria, it is considered 
that the microsomal GPAT activity was affected by 
vasopressin and Bu*cAMP. Because Pl was contami- 
nated by microsomes, vasopressin-induced alterations 
in GPAT could have been caused by microsomal con- 
tamination. However, when GPAT activity in Pl is 
expressed relative to Gd-Pase, there are significant 
(P < 0.05, n = 6) differences between control and 
vasopressin i cubations (not shown). This may indi- 
cate effects of vasopressin on mitochondrial GPAT. 
Furthermore, GPAT activities in Pl were greater than 
in P2 when expressed relative to GdPase or arylester- 
ase activity. We consider that this shows the presence 
of mitochondrial GPAT in PI. 
3.2. Effects of vasopressin on hepatocyte CAMP and 
glycerol-3ghosphate concentrations 
Because adipose tissue GPAT is possibly regulated 
by a CAMP-dependent phosphorylation mechanism 
[ 111, effects of vasopressin on hepatocyte CAMP con- 
centrations were investigated in the presence and 
absence of glucagon. There was no significant effect 
of vasopressin (10 nM) on basal CAMP concentrations 
in hepatocytes after 2-4 min exposure, nor was there 
any significant difference in CAMP concentrations 
between incubations (2-30 min) in the presence of a 
submaximal g ucagon concentration (0.5 nM, CAMP 
raised 2-3-fold) and 0.5 nM glucagon + 10 nM vaso- 
315 
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pressin. These results extend the observations of
others who found that vasopressin did not have any 
effect on basal CAMP concentrations in the perfused 
liver [6]. 
Changes in fatty acid esterification could be medi- 
ated by changes in glycerol-3-phosphate concentra- 
tion. There was no significant difference in glycerol- 
3-phosphate concentration between control and 
10 nM vasopressin ~cubations (0304 5 0.03 1 vs 
0287 f 0.039 mol/g wet wt cells, respectively, mean 
ZSEM, n = 4). There was a significant decrease in glyc- 
erol-3-phosphate concentration between control and 
10 nM glucagon incubations (0.304 If: 0.031 vs 
0.174 f 0.04, respectively, mean *SEM, n = 4, 
P < 0.05 paired t-test). Similar effects of glucagon 
have been observed 1261. 
4. Discussion 
Vasopressin creased the activities of GPAT and 
DDAPAT in rat hepatocyte homogenates orsubcel- 
h&r fractions. Glucagon and Bu+AMP decreased 
GPAT activities. We consider that these changes in 
enzyme activities may, at least in part, account for 
vasopressin-induced increases in fatty acid esterifica- 
tion in hepatocytes [S]. Glucagon or Bu@MP- 
induced decreases inhepatic fatty acid esterification 
[5 ,101 may be caused by decreases in glycerol-3-phos- 
phate concentrations andfor decreases in GPAT activ- 
ity in hepatocytes. Although the changes in enzyme 
activities we observed were relatively small, they are 
comparable with those seen by other investigators in, 
e.g., streptozoto~~d~betes 191. 
We presume that the effects of glucagon and 
BuacAMP on fatty acid esterification could be medi- 
ated by CAMP-dependent protein kinase-mediated 
phosphorylation (and inhibition) of GPAT [ 121. How 
vasopressin effects upon GPAT and DHAPAT activi- 
ties are mediated is not known. Although Ca2+ have 
been implicated in the effects of vasopressin on glyco- 
genolysis [ 11, they are not necessary for vasopressin- 
stimulated fatty acid esterification [7 1. Under the 
latter conditions (minus external Ca’+), vasopressin 
did not increase glucose release but did increase fatty 
acid este~~cation ( ot sham). 
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